277 related articles for article (PubMed ID: 7916899)
21. Quantitative dissociation between EGF effects on c-myc and c-fos gene expression, DNA synthesis, and epidermal growth factor receptor tyrosine kinase activity.
Hauguel-DeMouzon S; Csermely P; Zoppini G; Kahn CR
J Cell Physiol; 1992 Jan; 150(1):180-7. PubMed ID: 1730782
[TBL] [Abstract][Full Text] [Related]
22. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
23. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
24. Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells.
Gill GN; Buss JE; Lazar CS; Lifshitz A; Cooper JA
J Cell Biochem; 1982; 19(3):249-57. PubMed ID: 6296169
[TBL] [Abstract][Full Text] [Related]
25. Suppression by retinoic acid of epidermal growth factor receptor autophosphorylation and glycosylation in cultured human head and neck squamous carcinoma cells.
Kim JS; Steck PA; Gallick GE; Lee JS; Blick M; Hong WK; Lotan R
J Natl Cancer Inst Monogr; 1992; (13):101-10. PubMed ID: 1389683
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck.
Maxwell SA; Sacks PG; Gutterman JU; Gallick GE
Cancer Res; 1989 Mar; 49(5):1130-7. PubMed ID: 2783883
[TBL] [Abstract][Full Text] [Related]
27. Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells.
Castagnola J; MacLeod C; Sunada H; Mendelsohn J; Taetle R
J Cell Physiol; 1987 Sep; 132(3):492-500. PubMed ID: 3498729
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells.
Piontek M; Hengels KJ; Porschen R; Strohmeyer G
Anticancer Res; 1993; 13(6A):2119-23. PubMed ID: 8297123
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment.
Mermelstein FH; Abidi TF; Laskin JD
Mol Pharmacol; 1989 Dec; 36(6):848-55. PubMed ID: 2557535
[TBL] [Abstract][Full Text] [Related]
30. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
31. Regulation of the epidermal growth factor receptor by growth-modulating agents: effects of staurosporine, a protein kinase inhibitor.
Friedman B; Fujiki H; Rosner MR
Cancer Res; 1990 Feb; 50(3):533-8. PubMed ID: 1688732
[TBL] [Abstract][Full Text] [Related]
32. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
Han Y; Caday CG; Nanda A; Cavenee WK; Huang HJ
Cancer Res; 1996 Sep; 56(17):3859-61. PubMed ID: 8752145
[TBL] [Abstract][Full Text] [Related]
33. Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
Mishra S; Mathur R; Hamburger AW
Lymphokine Cytokine Res; 1994 Apr; 13(2):77-83. PubMed ID: 8061118
[TBL] [Abstract][Full Text] [Related]
34. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
[TBL] [Abstract][Full Text] [Related]
37. Activation of tyrosine kinases by alpha1A-adrenergic and growth factor receptors in transfected PC12 cells.
Zhong H; Minneman KP
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):889-94. PubMed ID: 10585878
[TBL] [Abstract][Full Text] [Related]
38. Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines.
Dangles V; Féménia F; Lainé V; Berthelemy M; Le Rhun D; Poupon MF; Levy D; Schwartz-Cornil I
Cancer Res; 1997 Aug; 57(16):3360-4. PubMed ID: 9269996
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
40. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
